Beckley Psytech

Company

Last mentioned: Mar 8, 2026

Timeline

Jun 1, 2026
Phase 3 Initiation

Expected launch of the global Phase 3 program for BPL-003 in TRD.
Mar 8, 2026
Results Announcement

Company reports 2025 results and confirms Phase 3 timeline.
Dec 31, 2025
Fiscal Year End

AtaiBeckley completes 2025 with focused R&D spending on lead assets.
Jan 1, 2024
Strategic Investment

atai Life Sciences invests $50M in Beckley Psytech to accelerate BPL-003.

Stories mentioning Beckley Psytech 1

AtaiBeckley Confirms Q2 2026 Phase 3 Launch for BPL-003 Following 2025 Results

AtaiBeckley has announced its 2025 financial results, highlighted by the upcoming Q2 2026 Phase 3 trial launch for its lead candidate, BPL-003. The intranasal 5-MeO-DMT compound is positioned as a potential blockbuster for treatment-resistant depression with a significantly shorter clinical footprint than existing therapies.

Mar 8, 2026 2 sources